Dr. Jeffrey Weber, deputy director of NYU Langone's Perlmutter Cancer Center, and principal investigator of a phase 2 study that provides the first randomized evidence that a personalized neoantigen approach may be beneficial for melanoma. Data from this clinical trial shows that an investigational personalized mRNA cancer vaccine, in combination with the immunotherapy pembrolizumab, is more effective against melanoma compared with those who received pembrolizumab alone.
Learn more about Dr. Jeffrey Weber's study: [ Ссылка ]
Learn more about Dr. Jeffrey Weber: [ Ссылка ]
